Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT01282463
Brief Title: Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

First Submitted : January 21, 2011
First Submitted that Met QC Criteria : January 21, 2011
First Posted : January 25, 2011 (Estimate)

Results First Submitted : June 13, 2019
Results First Submitted that Met QC Criteria : June 13, 2019
Results First Posted : July 2, 2019

Certification/Extension First Submitted : May 8, 2015
Certification/Extension First Submitted that Met QC Criteria : May 8, 2015
Certification/Extension First Posted : May 25, 2015 (Estimate)

Last Update Submitted that Met QC Criteria : August 26, 2019
Last Update Posted : September 9, 2019